Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin

References

• ConroyTDesseigneFYchouMGroupe Tumeurs Digestives of UnicancerPRODIGE IntergroupFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• ChurillaTMLeskoSLBreretonHDKlemMDonnellyPEPetersCASerum vitamin D levels among patients in a clinical oncology practice compared to primary care patients in the same community: a case-control studyBMJ Open201112e000397
   PubMed Web of Science ®Google Scholar
• ChurillaTMBreretonHDKlemMPetersCAVitamin D deficiency is widespread in cancer patients and correlates with advanced stage disease: a community oncology experienceNutr Cancer201264452152522452722
   PubMed Web of Science ®Google Scholar
• SkinnerHGMichaudDSGiovannucciEWillettWCColditzGAFuchsCSVitamin D intake and the risk for pancreatic cancer in two cohort studiesCancer Epidemiol Biomarkers Prev20061591688169516985031
   PubMed Web of Science ®Google Scholar
• WolpinBMNgKBaoYPlasma 25-hydroxyvitamin D and risk of pancreatic cancerCancer Epidemiol Biomarkers Prev2012211829122086883
   PubMed Web of Science ®Google Scholar
• ApteMVWilsonJSDangerous liaisons: pancreatic stellate cells and pancreatic cancer cellsJ Gastroenterol Hepatol201227Suppl 26974
   PubMedGoogle Scholar
• ShermanMHYuRTEngleDDVitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapyCell20141591809325259922
   PubMed Web of Science ®Google Scholar
• SchwartzGGEadsDNaczkiCNorthrupSChenTKoumenisC19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivoCancer Biol Ther20087343043618094617
   PubMed Web of Science ®Google Scholar
• O’DwyerPJShermanMJohnstonKA randomized pilot/pharmacodynamic/genomic study of neoadjuvant paricalcitol to target the microenvironment in resectable pancreatic cancer: a SU2C trialAmerican Society of Clinical Oncology Annual ConferenceJune 2nd 2015Chicago, IL
   Google Scholar
• BorazanciEHJamesonGSBoradMJA phase II pilot trial of nivolumab + albumin bound paclitaxel + paricalcitol + cisplatin + gemcitabine (NAPPCG) in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinomaJ Clin Oncol201735Suppl 4TPS511
   Web of Science ®Google Scholar
• ChakrabortiCKVitamin D as a promising anticancer agentIndian J Pharmacol201143211312021572642
   PubMed Web of Science ®Google Scholar
• AudoIDarjatmokoSRSchlampCLVitamin D analogues increase p53, p21, and apoptosis in a xenograft model of human retinoblastomaInvest Ophthalmol Vis Sci200344104192419914507860
   PubMed Web of Science ®Google Scholar
• KalkunteSBrardLGranaiCOSwamyNInhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-mafAngiogenesis20058434936016400520
   PubMedGoogle Scholar
• SpragueSMLlachFAmdahlMTaccettaCBatlleDParicalcitol versus calcitriol in the treatment of secondary hyperparathyroidismKidney Int20036341483149012631365
   PubMed Web of Science ®Google Scholar
• SchwartzGGHallMCStindtDPattonSLovatoJTortiFMPhase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancerClin Cancer Res20051124 Pt 18680868516361554
   PubMed Web of Science ®Google Scholar
• ChoiAMRyterSWLevineBAutophagy in human health and diseaseN Engl J Med2013368765166223406030
   PubMed Web of Science ®Google Scholar
• WhiteEThe role for autophagy in cancerJ Clin Invest20151251424625654549
   PubMed Web of Science ®Google Scholar
• RubinszteinDCGestwickiJEMurphyLOKlionskyDJPotential therapeutic applications of autophagyNat Rev Drug Discov20076430431217396135
   PubMed Web of Science ®Google Scholar
• PereraRMBardeesyNPancreatic cancer metabolism: breaking it down to build it back upCancer Discov20155121247126126534901
   PubMed Web of Science ®Google Scholar
• WhiteEDeconvoluting the context-dependent role for autophagy in cancerNat Rev Cancer201212640141022534666
   PubMed Web of Science ®Google Scholar
• YangSWangXContinoGPancreatic cancers require autophagy for tumor growthGenes Dev201125771772921406549
   PubMed Web of Science ®Google Scholar
• WolpinBMRubinsonDAWangXPhase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinomaOncologist201419663763824821822
   PubMed Web of Science ®Google Scholar
• HongTSWoJYJiangWPhase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC)J Clin Oncol201735Suppl 154118
   Google Scholar
• Miller-OcuinJLBaharyNSSinghiADInhibition of autophagy improves pathologic and biomarker response to preoperative gemcitabine/Nab-paclitaxel in potentially resectable pancreatic cancer: a phase II randomized controlled trialAnn Surg Oncol201724Suppl 1s6
   PubMedGoogle Scholar
• MarmorMFKellnerULaiTYMellesRBMielerWFAmerican Academy of OphthalmologyRecommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)Ophthalmology201612361386139426992838
   PubMed Web of Science ®Google Scholar
• LeungLSNealJWWakeleeHASequistLVMarmorMFRapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapyAm J Ophthalmol20151604799805.e126189086
   PubMed Web of Science ®Google Scholar
• CameronECampbellAThe orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancerChem Biol Interact1974942853154430016
   PubMed Web of Science ®Google Scholar
• CameronEPaulingLSupplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancerProc Natl Acad Sci U S A197875945384542279931
   PubMed Web of Science ®Google Scholar
• NechutaSLuWChenZVitamin supplement use during breast cancer treatment and survival: a prospective cohort studyCancer Epidemiol Biomarkers Prev201120226227121177425
   PubMed Web of Science ®Google Scholar
• HarrisHROrsiniNWolkAVitamin C and survival among women with breast cancer: a meta-analysisEur J Cancer20145071223123124613622
   PubMed Web of Science ®Google Scholar
• CreaganETMoertelCGO’FallonJRFailure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trialN Engl J Med197930113687690384241
   PubMed Web of Science ®Google Scholar
• MoertelCGFlemingTRCreaganETRubinJO’ConnellMJAmesMMHigh-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparisonN Engl J Med198531231371413880867
   PubMed Web of Science ®Google Scholar
• PadayattySJSunHWangYVitamin C pharmacokinetics: implications for oral and intravenous useAnn Intern Med2004140753353715068981
   PubMed Web of Science ®Google Scholar
• LevineMConry-CantilenaCWangYVitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowanceProc Natl Acad Sci U S A1996938370437098623000
   PubMed Web of Science ®Google Scholar
• GraumlichJFLuddenTMConry-CantilenaCCantilenaLRJrWangYLevineMPhamacokinetic model for ascorbic acid in healthy male volunteers during depletion and repletionPharm Res1997149113311399327438
   PubMed Web of Science ®Google Scholar
• HofferLJLevineMAssoulineSPhase I clinical trial of i.v. ascorbic acid in advanced malignancyAnn Oncol200819111969197418544557
   PubMed Web of Science ®Google Scholar
• DoskeyCMBuranasudjaVWagnerBATumor cells have decreased ability to metabolize H2O2: implications for pharmacological ascorbate in cancer therapyRedox Biol20161027428427833040
   PubMed Web of Science ®Google Scholar
• DuJMartinSMLevineMMechanisms of ascorbate-induced cytotoxicity in pancreatic cancerClin Cancer Res201016250952020068072
   PubMed Web of Science ®Google Scholar
• EspeyMGChenPChalmersBPharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancerFree Radic Biol Med201150111610161921402145
   PubMed Web of Science ®Google Scholar
• DuJDoskeyCMWilkesJGBuettnerGRCullenJJCatalase as a potential biomarker of pharmacological ascorbate cancer therapyFree Radic Biol Med2016100S121
   Web of Science ®Google Scholar
• YunJMullarkyELuCVitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDHScience201535062661391139626541605
   PubMed Web of Science ®Google Scholar
• KlingelhoefferCKammererUKoospalMNatural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stressBMC Complement Altern Med2012126122551313
   PubMed Web of Science ®Google Scholar
• AguileraOMunoz-SagastibelzaMTorrejonBVitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancerOncotarget2016730479544796527323830
   PubMedGoogle Scholar
• BonuccelliGDe FrancescoEMde BoerRTanowitzHBLisantiMPNADH autofluorescence, a new metabolic biomarker for cancer stem cells: identification of vitamin C and CAPE as natural products targeting “stemness”Oncotarget2017813206672067828223550
   PubMedGoogle Scholar
• ChenPStoneJSullivanGDriskoJAChenQAnti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer modelsFree Radic Biol Med201151368168721672627
   PubMed Web of Science ®Google Scholar
• ChenQEspeyMGKrishnaMCPharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissuesProc Natl Acad Sci U S A200510238136041360916157892
   PubMed Web of Science ®Google Scholar
• VerraxJCalderonPBPharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effectsFree Radic Biol Med2009471324019254759
   PubMed Web of Science ®Google Scholar
• FrömbergAGutschDSchulzeDAscorbate exerts antiproliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugsCancer Chemother Pharmacol20116751157116620694726
   PubMed Web of Science ®Google Scholar
• ChenPYuJChalmersBPharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagyAnticancer Drugs201223443744422205155
   PubMed Web of Science ®Google Scholar
• LinZYChuangWLPharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell linesBiomed Pharmacother201064534835119932582
   PubMed Web of Science ®Google Scholar
• PathiSSLeiPSreevalsanSChadalapakaGJutooruISafeSPharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cellsNutr Cancer20116371133114221919647
   PubMed Web of Science ®Google Scholar
• TakemuraYSatohMSatohKHamadaHSekidoYKubotaSHigh dose of ascorbic acid induces cell death in mesothelioma cellsBiochem Biophys Res Commun2010394224925320171954
   PubMed Web of Science ®Google Scholar
• HardawayCMBadisaRBSolimanKFEffect of ascorbic acid and hydrogen peroxide on mouse neuroblastoma cellsMol Med Rep2012561449145222469841
   PubMed Web of Science ®Google Scholar
• PengLJLuDXQiRBZhangTWangZSunYTherapeutic effect of intravenous high-dose vitamin C on implanted hepatoma in ratsNan Fang Yi Ke Da Xue Xue Bao2009292264266 Chinese [with English abstract]19246295
   PubMedGoogle Scholar
• ChenQEspeyMGSunAYPharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in miceProc Natl Acad Sci U S A200810532111051110918678913
   PubMed Web of Science ®Google Scholar
• WelshJLWagnerBAvan’t ErveTJPharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trialCancer Chemother Pharmacol201371376577523381814
   PubMed Web of Science ®Google Scholar
• MontiDAMitchellEBazzanAJPhase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerPLoS One201271e2979422272248
   PubMed Web of Science ®Google Scholar
• CullenJJAscorbate induces autophagy in pancreatic cancerAutophagy20106342142220400857
   PubMed Web of Science ®Google Scholar
• SanchoPBurgos-RamosETaveraAMYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cellsCell Metab201522459060526365176
   PubMed Web of Science ®Google Scholar
• AndrzejewskiSGravelSPPollakMSt-PierreJMetformin directly acts on mitochondria to alter cellular bioenergeticsCancer Metab201421225184038
   PubMedGoogle Scholar
• MatsubaraSDingQMiyazakiYKuwahataTTsukasaKTakaoSmTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functionsSci Rep20133323024231729
   PubMed Web of Science ®Google Scholar
• IncioJSubojPChinSMMetformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophagesPLoS One20151012e014139226641266
   PubMed Web of Science ®Google Scholar
• DuanWChenKJiangZDesmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progressionCancer Lett201738522523327773749
   PubMed Web of Science ®Google Scholar
• BaoBWangZAliSMetformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cellsCancer Prev Res (Phila)20125335536422086681
   PubMed Web of Science ®Google Scholar
• HirschHAIliopoulosDTsichlisPNStruhlKMetformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remissionCancer Res200969197507751119752085
   PubMed Web of Science ®Google Scholar
• MohammedAJanakiramNBBrewerMAntidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signalingTransl Oncol20136664965924466367
   PubMed Web of Science ®Google Scholar
• SchneiderMBMatsuzakiHHaorahJPrevention of pancreatic cancer induction in hamsters by metforminGastroenterology200112051263127011266389
   PubMed Web of Science ®Google Scholar
• KisfalviKMoroASinnett-SmithJEiblGRozengurtEMetformin inhibits the growth of human pancreatic cancer xenograftsPancreas201342578178523462329
   PubMed Web of Science ®Google Scholar
• CifarelliVLashingerLMDevlinKLMetformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanismsDiabetes20156451632164225576058
   PubMed Web of Science ®Google Scholar
• CurrieCJPooleCDGaleEAThe influence of glucose-lowering therapies on cancer risk in type 2 diabetesDiabetologia20095291766177719572116
   PubMed Web of Science ®Google Scholar
• LiDYeungSCHassanMMKonoplevaMAbbruzzeseJLAntidiabetic therapies affect risk of pancreatic cancerGastroenterology2009137248248819375425
   PubMed Web of Science ®Google Scholar
• AmbeCMMahipalAFulpJChenLMalafaMPEffect of metformin use on survival in resectable pancreatic cancer: a single-institution experience and review of the literaturePLoS One2016113e015163226967162
   PubMed Web of Science ®Google Scholar
• SadeghiNAbbruzzeseJLYeungSCHassanMLiDMetformin use is associated with better survival of diabetic patients with pancreatic cancerClin Cancer Res201218102905291222465831
   PubMed Web of Science ®Google Scholar
• KordesSPollakMNZwindermanAHMetformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trialLancet Oncol201516783984726067687
   PubMed Web of Science ®Google Scholar
• ReniMDugnaniECeredaS(Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized Phase II trialClin Cancer Res20162251076108526459175
   PubMed Web of Science ®Google Scholar
• ChaiteerakijRPetersenGMBamletWRMetformin use and survival of patients with pancreatic cancer: a cautionary lessonJ Clin Oncol201634161898190427069086
   PubMed Web of Science ®Google Scholar
• J-YES-ELuLinYEffects of concomitant metformin and statins on overall survival of pancreatic cancer patients: results from SEER-Medicare data analysesCancer Res20177713 abstr 3288
   Google Scholar
• BathaieSZAshrafiMAzizianMTamanoiFMevalonate pathway and human cancersCurr Mol Pharmacol2017102778526758953
   PubMed Web of Science ®Google Scholar
• LeeHSLeeSHLeeHJStatin use and its impact on survival in pancreatic cancer patientsMedicine (Baltimore)20169519e360727175667
   PubMed Web of Science ®Google Scholar
• VillarinoNSignaevskaiaLvan NiekerkJA screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancerOncotarget2017832531545316728881801
   PubMedGoogle Scholar
• LiaoJChungYTYangALAtorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre miceMol Carcinog201352973975022549877
   PubMed Web of Science ®Google Scholar
• CheemaAHassanHQureshiWShakeelMSaifWEffect of statins on risk of pancreatic cancer: a meta-analysis of randomized controlled trials (RCTs) and observational studies (OS)J Clin Oncol201634 abstr e15751
   Google Scholar
• KhuranaVShethACalditoGBarkinJSStatins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veteransPancreas200734226026517312467
   PubMed Web of Science ®Google Scholar
• GoldsteinMRMascitelliLPezzettaFDo statins prevent or promote cancer?Curr Oncol2008152767718454187
   PubMed Web of Science ®Google Scholar
• HuangBZChangJILiEXiangAHWuBUInfluence of statins and cholesterol on mortality among patients with pancreatic cancerJ Natl Cancer Inst20171095djw27528040693
   PubMedGoogle Scholar
• WuBUChangJJeonCYImpact of statin use on survival in patients undergoing resection for early-stage pancreatic cancerAm J Gastroenterol201511081233123926195180
   PubMed Web of Science ®Google Scholar
• JeonCYPandolSJWuBThe association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysisPLoS One2015104e012178325830309
   PubMed Web of Science ®Google Scholar
• NielsenSFNordestgaardBGBojesenSEStatin use and reduced cancer-related mortalityN Engl J Med2012367191792180223134381
   PubMed Web of Science ®Google Scholar
• HongJYNamEMLeeJRandomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patientsCancer Chemother Pharmacol201473112513024162380
   PubMed Web of Science ®Google Scholar
• Moon doCLeeHSLeeYIConcomitant statin use has a favorable effect on gemcitabine-erlotinib combination chemotherapy for advanced pancreatic cancerYonsei Med J20165751124113027401642
   PubMed Web of Science ®Google Scholar
• BimonteSCascellaMLeongitoMAn overview of pre-clinical studies on the effects of (−)-epigallocatechin-3-gallate, a catechin found in green tea, in treatment of pancreatic cancerRecenti Prog Med2017108628228728631776
   PubMedGoogle Scholar
• BimonteSLeongitoMBarbieriAInhibitory effect of (−)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growthInfect Agents Cancer20151012226225138
   PubMedGoogle Scholar
• BimonteSBarbieriALeongitoMCurcumin anticancer studies in pancreatic cancerNutrients201687E43327438851
   PubMed Web of Science ®Google Scholar
• BimonteSBarbieriALeongitoMThe role of miRNAs in the regulation of pancreatic cancer stem cellsStem Cells Int20162016835268427006664
   PubMed Web of Science ®Google Scholar
• LiYGoVLSarkarFHThe role of nutraceuticals in pancreatic cancer prevention and therapy: targeting cellular signaling, miRNAs and epigenomePancreas201544111025493373
   PubMed Web of Science ®Google Scholar
• KanaiMTherapeutic applications of curcumin for patients with pancreatic cancerWorld J Gastroenterol201420289384939125071333
   PubMed Web of Science ®Google Scholar
• LiLAggarwalBBShishodiaSAbbruzzeseJKurzrockRNuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosisCancer2004101102351236215476283
   PubMed Web of Science ®Google Scholar
• KunnumakkaraABDiagaradjanePGuhaSCurcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene productsClin Cancer Res20081472128213618381954
   PubMed Web of Science ®Google Scholar
• SahuRPBatraSSrivastavaSKActivation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cellsBr J Cancer200910091425143319401701
   PubMed Web of Science ®Google Scholar
• GlienkeWMauteLWichtJBergmannLCurcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and down-regulation of survivin/BIRC5 gene expressionCancer Invest201028216617120121547
   PubMed Web of Science ®Google Scholar
• JutooruIChadalapakaGLeiPSafeSInhibition of NFkap-paB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulationJ Biol Chem201028533253322534420538607
   PubMed Web of Science ®Google Scholar
• AliSAhmadABanerjeeSGemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDFCancer Res20107093606361720388782
   PubMed Web of Science ®Google Scholar
• YounsMFathyGMUpregulation of extrinsic apoptotic pathway in curcumin-mediated antiproliferative effect on human pancreatic carcinogenesisJ Cell Biochem2013114122654266523794119
   PubMed Web of Science ®Google Scholar
• LiYRevaldeJLReidGPaxtonJWModulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cellsCancer Chemother Pharmacol201168360361021116627
   PubMed Web of Science ®Google Scholar
• KunnumakkaraABGuhaSKrishnanSDiagaradjanePGelovaniJAggarwalBBCurcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene productsCancer Res20076783853386117440100
   PubMed Web of Science ®Google Scholar
• FujiokaSSonKOndaSDesensitization of NFkappaB for overcoming chemoresistance of pancreatic cancer cells to TNF-alpha or paclitaxelAnticancer Res201232114813482123155247
   PubMed Web of Science ®Google Scholar
• UwagawaTYanagaKEffect of NF-kappaB inhibition on chemoresistance in biliary-pancreatic cancerSurg Today201545121481148825673034
   PubMed Web of Science ®Google Scholar
• ArltAGehrzAMuerkosterSRole of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell deathOncogene200322213243325112761494
   PubMed Web of Science ®Google Scholar
• YoshidaKTodenSRavindranathanPHanHGoelACurcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expressionCarcinogenesis201738101036104629048549
   PubMed Web of Science ®Google Scholar
• GuptaSCSungBKimJHPrasadSLiSAggarwalBBMultitargeting by turmeric, the golden spice: from kitchen to clinicMol Nutr Food Res20135791510152822887802
   PubMed Web of Science ®Google Scholar
• FerrucciLMDanielCRKapurKMeasurement of spices and seasonings in India: opportunities for cancer epidemiology and preventionAsian Pac J Cancer Prev20101161621162921338207
   PubMedGoogle Scholar
• ParkWAminARChenZGShinDMNew perspectives of curcumin in cancer preventionCancer Prev Res (Phila)20136538740023466484
   PubMed Web of Science ®Google Scholar
• SingletaryKMacDonaldCWalligMFisherCInhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcuminCancer Lett199610321371418635149
   PubMed Web of Science ®Google Scholar
• UshidaJSugieSKawabataKChemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in ratsJpn J Cancer Res200091989389811011116
   PubMedGoogle Scholar
• PerkinsSVerschoyleRDHillKChemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposisCancer Epidemiol Biomarkers Prev200211653554012050094
   PubMed Web of Science ®Google Scholar
• PrasadSTyagiAKAggarwalBBRecent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spiceCancer Res Treat201446121824520218
   PubMed Web of Science ®Google Scholar
• SurhYJChunKSChaHHMolecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activationMutat Res2001480–481243268
   PubMed Web of Science ®Google Scholar
• SunXDLiuXEHuangDSCurcumin reverses the epithelial-mesenchymal transition of pancreatic cancer cells by inhibiting the Hedgehog signaling pathwayOncol Rep20132962401240723563640
   PubMed Web of Science ®Google Scholar
• Díaz OstermanCJGondaAStiffTCurcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosisPancreas201645110110926348467
   PubMed Web of Science ®Google Scholar
• BimonteSBarbieriAPalmaGLucianoAReaDArraCCurcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancerBiomed Res Int2013201381042324324975
   PubMed Web of Science ®Google Scholar
• ArltASchaferHKalthoffHThe ‘N-factors’ in pancreatic cancer: functional relevance of NF-kappaB, NFAT and Nrf2 in pancreatic cancerOncogenesis20121e3523552468
   PubMed Web of Science ®Google Scholar
• Diaz OstermanCJWallNRCurcumin and pancreatic cancer: a research and clinical updateJ Nat Sci201516e124
   Google Scholar
• AnandPKunnumakkaraABNewmanRAAggarwalBBBioavailability of curcumin: problems and promisesMol Pharm20074680781817999464
   PubMed Web of Science ®Google Scholar
• LaoCDRuffinMT4thNormolleDDose escalation of a curcuminoid formulationBMC Complement Altern Med200661016545122
   PubMedGoogle Scholar
• VareedSKKakaralaMRuffinMTPharmacokinetics of curcumin conjugate metabolites in healthy human subjectsCancer Epidemiol Biomarkers Prev20081761411141718559556
   PubMed Web of Science ®Google Scholar
• GarceaGBerryDPJonesDJConsumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequencesCancer Epidemiol Biomarkers Prev200514112012515668484
   PubMed Web of Science ®Google Scholar
• DhillonNAggarwalBBNewmanRAPhase II trial of curcumin in patients with advanced pancreatic cancerClin Cancer Res200814144491449918628464
   PubMed Web of Science ®Google Scholar
• KanaiMYoshimuraKAsadaMA phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancerCancer Chemother Pharmacol201168115716420859741
   PubMed Web of Science ®Google Scholar
• KanaiMImaizumiAOtsukaYDose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteersCancer Chemother Pharmacol2012691657021603867
   PubMed Web of Science ®Google Scholar
• KanaiMOtsukaYOtsukaKA phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patientsCancer Chemother Pharmacol20137161521153023543271
   PubMed Web of Science ®Google Scholar
• SasakiHSunagawaYTakahashiKInnovative preparation of curcumin for improved oral bioavailabilityBiol Pharm Bull201134566066521532153
   PubMed Web of Science ®Google Scholar
• SunagawaYHiranoSKatanasakaYColloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover studyJ Nutr Sci Vitaminol (Tokyo)2015611374425994138
   PubMed Web of Science ®Google Scholar
• ChanATOginoSFuchsCSAspirin use and survival after diagnosis of colorectal cancerJAMA20173026649658
   Google Scholar
• HolmesMDChenWYLiLHertzmarkESpiegelmanDHankinsonSEAspirin intake and survival after breast cancerJ Clin Oncol20102891467147220159825
   PubMed Web of Science ®Google Scholar
• UlrichCMBiglerJPotterJDNon-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogeneticsNat Rev Cancer20066213014016491072
   PubMed Web of Science ®Google Scholar
• ChanATGiovannucciELMeyerhardtJASchernhammerESCurhanGCFuchsCSLong-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancerJAMA2005294891492316118381
   PubMed Web of Science ®Google Scholar
• MahipalAAndersonKELimburgPJFolsomARNonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women’s health studyCancer Epidemiol Biomarkers Prev200615101785179017035383
   PubMed Web of Science ®Google Scholar
• TanXLNietersAHoffmeisterMBeckmannLBrennerHChang-ClaudeJGenetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?Pharmacogenet Genomics200717863964517622940
   PubMed Web of Science ®Google Scholar
• ColletJPSharpeCBelzileEBoivinJFHanleyJAbenhaimLColorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timingBr J Cancer1999811626810487613
   PubMed Web of Science ®Google Scholar
• SandlerRSHalabiSBaronJAA randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancerN Engl J Med20033481088389012621132
   PubMed Web of Science ®Google Scholar
• González-PérezAGarcía RodríguezLALópez-RidauraREffects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysisBMC Cancer200332814588079
   PubMed Web of Science ®Google Scholar
• KasumCMBlairCKFolsomARRossJANon-steroidal anti-inflammatory drug use and risk of adult leukemiaCancer Epidemiol Biomarkers Prev200312653453712814999
   PubMed Web of Science ®Google Scholar
• HarrisREChlebowskiRTJacksonRDBreast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health InitiativeCancer Res2003636096610114522941
   PubMed Web of Science ®Google Scholar
• MarshallSFBernsteinLAnton-CulverHNonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor statusJ Natl Cancer Inst20059780581215928301
   PubMed Web of Science ®Google Scholar
• PrizmentAEFolsomARAndersonKENonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women’s Health StudyCancer Epidemiol Biomarkers Prev201019243544220142241
   PubMed Web of Science ®Google Scholar
• ViswanathanANFeskanichDSchernhammerESHankinsonSEAspirin, NSAID, and acetaminophen use and the risk of endometrial cancerCancer Res20086872507251318381460
   PubMed Web of Science ®Google Scholar
• JacobsEJRodriguezCMondulAMA large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidenceJ Natl Cancer Inst2005971397598015998950
   PubMedGoogle Scholar
• SalinasCAKwonEMFitzGeraldLMUse of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer riskAm J Epidemiol2010172557859020688905
   PubMed Web of Science ®Google Scholar
• RischHALuLStreicherSAAspirin use and reduced risk of pancreatic cancerCancer Epidemiol Biomarkers Prev2017261687427999143
   PubMed Web of Science ®Google Scholar
• StreicherSAYuHLuLKiddMSRischHACase-control study of aspirin use and risk of pancreatic cancerCancer Epidemiol Biomarkers Prev20142371254126324969230
   PubMed Web of Science ®Google Scholar
• AndersonKEJohnsonTWLazovichDFolsomARAssociation between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancerJ Natl Cancer Inst200294151168117112165642
   PubMedGoogle Scholar
• TanXLReid LombardoKMBamletWRAspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control studyCancer Prev Res (Phila)20114111835184121803981
   PubMed Web of Science ®Google Scholar
• ArchibugiLPiciucchiMStiglianoSExclusive and combined use of statins and aspirin and the risk of pancreatic cancer: a case-control studySci Rep2017711302429026148
   PubMedGoogle Scholar
• ElwoodPCMorganGPickeringJEAspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studiesPLoS One2016114e015240227096951
   PubMed Web of Science ®Google Scholar
• MitrugnoASylmanJLNgoATAspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYCAm J Physiol Cell Physiol20173122C176C18927903583
   PubMed Web of Science ®Google Scholar
• AiGDachineniRMuleyPTummalaHBhatGJAspirin and salicylic acid decrease c-Myc expression in cancer cells: a potential role in chemopreventionTumour Biol20163721727173826314861
   PubMedGoogle Scholar
• RothwellPMWilsonMPriceJFBelchJFMeadeTWMehtaZEffect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomized controlled trialsLancet201237998261591160122440947
   PubMed Web of Science ®Google Scholar
• YangLZhuHLiuDAspirin suppresses growth of human gastric carcinoma cell by inhibiting survivin expressionJ Biomed Res201125424625323554697
   PubMedGoogle Scholar